West Pharmaceutical Services, Inc. research snapshot
WST AI stock analysis currently reads West Pharmaceutical Services as a high-quality supplier of injectable drug containment, elastomer components, self-injection devices, and contract manufacturing services. At the July 9, 2026 data cutoff, WST traded near $353.68 after hours, and the audited market cap check produced about $25.76 billion using 72.845 million shares. The positive case is that High-Value Product Components, GLP-1 and non-GLP-1 biologics demand, self-injection devices, customer quality requirements, and raised 2026 guidance can support earnings growth. The caution is valuation: WST trades near 47x TTM EPS and about 56x TTM free cash flow per share, so the WST AI stock forecast needs continued organic growth, margin delivery, and customer stability.
Current price
$353.68 after-hours reference
Market cap
$25.76 billion verified market cap
AI score
72 / 100
Rating
High-quality injectable packaging and drug delivery supplier with GLP-1 demand exposure, customer concentration, and premium valuation risk
Trend status
Constructive long-term trend with neutral short-term momentum, price above the 50-day and 200-day averages
Data cutoff (updated weekly)
July 9, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | West sells mission-critical injectable packaging, elastomer components, containment systems, self-injection device platforms, and West Vantage contract manufacturing services to drug developers and pharmaceutical companies. | High |
| Moat | The moat comes from regulatory qualification, product quality, customer validation, switching costs, process know-how, scale, proprietary high-value components, and long relationships with injectable drug makers. | High |
| Management | CEO Eric Green has emphasized high-value product mix, global capacity, disciplined capital spending, dividends, buybacks, and the SmartDose 3.5mL sale to AbbVie. The test is whether capital goes into returns above the current premium multiple. | Medium-high |
| Financial trend | FY2025 revenue was $3.074 billion, FY2025 net income was $493.7 million, and Q1 2026 revenue rose 21.0% to $844.9 million with diluted EPS of $1.92. | High |
| Valuation | At $353.68, audited math shows about 47.3x TTM EPS, 56.1x TTM free cash flow per share, 8.6x book value, and 8.0x sales per share. The valuation requires sustained execution. | High |
| Technical trend | Technical readings are constructive but not risk-free: price is above the 50-day and 200-day averages, RSI is neutral near 60, while MACD was cited as bearish by a technical data provider. | Medium |
| Risk level | Key risks include customer concentration, injectable inventory cycles, GLP-1 demand normalization, quality or regulatory failures, margin pressure, capex execution, currency, and multiple compression. | Medium-high |
| AI confidence | Descriptive confidence is high because filings and data services align on the core base. Return confidence is lower because WST depends on future growth, customer mix, and a premium valuation. | High data confidence |
| Investment certainty | WST is a high-quality life science supplier, but the current price leaves limited room for another demand, inventory, or guidance disappointment. | Medium |
WST AI stock forecast
The WST AI stock forecast uses the $353.68 price reference, TTM EPS of $7.48, and a three-year earnings multiple framework. The audited model produced a bearish value near $222.30, a base value near $358.10, and a bullish value near $472.90 before dividends. These are scenario ranges, not promises.
$450 to $485
More likely if organic revenue growth stays near or above the 7% to 9% 2026 guidance range, HVP Components and delivery devices keep compounding, GLP-1 and non-GLP-1 demand remain strong, operating margins expand, and investors keep valuing WST near a premium mid-40s earnings multiple.
$345 to $370
More likely if EPS compounds around high single digits, 2026 guidance is met, the SmartDose transaction closes as assumed, free cash flow remains healthy, and the stock holds a high-30s earnings multiple.
$210 to $235
More likely if customer inventory normalization returns, GLP-1 demand or HVP mix disappoints, one large customer reduces orders, quality costs rise, margins fail to expand, or WST re-rates toward a lower medical-supplies multiple.
WST AI technical analysis
WST AI technical analysis uses market and technical data available at the July 9, 2026 cutoff. StockAnalysis showed WST at $352.28 at the July 8 close and $353.68 after hours. AltIndex showed RSI near 60, a 50-day moving average near $332.50, a 200-day moving average near $280.70, and a strong-buy aggregate technical signal, while also flagging bearish MACD. ChartMill showed a more cautious short-term setup with support around $271 to $274 and resistance around $275 to $297 on its referenced page, so the technical levels should be treated as provider-specific snapshots.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $353.68 | After-hours quote reference shown by StockAnalysis on July 8, 2026 and used for this static page at the July 9, 2026 data cutoff. |
| Immediate support | $332 to $335 | Area around the 50-day moving average and prior resistance reference cited by technical data providers. |
| Deeper support | $300 to $310 | Approximate reset zone near the 100-day area and a level where a pullback would test whether the recovery trend remains intact. |
| Long-term support | $280 to $281 | Area around the 200-day moving average cited by AltIndex, important for the longer-term trend. |
| Near resistance | $360 to $370 | Short-term overhead area after the move above the 50-day average. A close above this range would need volume confirmation. |
| Major resistance | $400 to $410 | Psychological and prior rerating zone where the premium valuation would face a stronger test. |
| Moving averages | 50-day about $332.50, 200-day about $280.70 | The 50-day moving average above the 200-day average is constructive, but it does not remove valuation or earnings risk. |
| Momentum | RSI near 60, MACD bearish | Momentum is not overbought by RSI, but MACD caution argues against treating the chart as a one-way trend. |
| Volume | Confirm breakouts above $360 to $370 | A technical breakout should be paired with stronger volume and no negative guidance update. |
| Invalidation | Sustained close below $300 | A durable break below the 100-day zone would weaken the recovery setup and shift attention to valuation reset risk. |
WST AI trading strategy
The WST AI trading strategy below is a rules-based research framework, not personalized advice. It connects price action with organic growth, HVP mix, Q2 2026 guidance, SmartDose transaction timing, free cash flow, customer concentration, and valuation discipline.
Watch for WST to hold above the $332 to $335 moving-average area and break the $360 to $370 resistance zone while Q2 results confirm net sales guidance of $830 million to $850 million, adjusted EPS of $2.05 to $2.12, and continued HVP growth.
A failed reclaim after earnings, a close below $332, weaker organic growth, or margin commentary that challenges the raised 2026 guide should reduce trend-following confidence.
If WST pulls back toward $300 to $310 without a thesis break, compare the lower price with updated 2026 EPS guidance, free cash flow per share, customer demand, GLP-1 order visibility, and peer medical-supplies multiples.
Do not treat a lower price as automatically attractive if the pullback is caused by a major customer loss, quality issue, inventory correction, or a lower earnings guide.
Track HVP Components sales, HVP Delivery Devices sales, West Vantage growth, gross margin, operating margin, cash conversion, capex, share repurchases, dividends, SmartDose sale timing, and the percentage of sales from the largest customers.
Position sizing should reflect that WST is a strong business with a high multiple. Even good companies can fall sharply when expectations reset.
Investment research summary
Customers pay West because injectable medicines need validated containment, delivery, component quality, and manufacturing reliability. Once a drug is approved with qualified components, switching suppliers can be slow, costly, and risky.
The moat is built on regulatory qualification, product science, quality systems, customer validation, manufacturing scale, high-value elastomer components, self-injection device know-how, and long pharmaceutical development cycles.
The thesis fails if GLP-1 demand slows, inventory correction returns, one large customer changes sourcing, a quality issue damages trust, SmartDose economics disappoint, or the premium valuation compresses faster than EPS grows.
Management has focused on high-value product mix, global capacity, disciplined capex, dividends, buybacks, and portfolio focus. Capital allocation quality depends on sustaining returns after the stock already recovered from its 2025 guidance reset.
Injectable biologics, GLP-1 therapies, self-injection, sterile drug delivery, and pharmaceutical outsourcing support long-term demand. The offset is that customer inventory cycles and product concentration can create sharp earnings revisions.
At $353.68, WST is priced as a premium compounder, not a deep-value stock. The three-scenario model shows limited base-case upside unless EPS growth and a high earnings multiple both persist.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $352.28 at July 8, 2026 close and $353.68 after hours on StockAnalysis | StockAnalysis WST balance sheet quote header | July 9, 2026 |
| Market capitalization verification | $25.76 billion calculated from $353.68 x 72.845 million shares | Pineify financial_rigor.py and WST share data | July 9, 2026 |
| Shares outstanding | 72.0 million average common shares in Q1 2026, 72.021 million shares outstanding on January 29, 2026, and about 73 million 2025 shares from Macrotrends | West Q1 2026 release and 2025 Form 10-K | July 9, 2026 |
| FY2025 revenue | $3.074 billion, cross-validated against West release, StockAnalysis, and Macrotrends | West FY2025 results | July 9, 2026 |
| FY2025 net income | $493.7 million, cross-validated against StockAnalysis and Macrotrends | StockAnalysis WST income statement | July 9, 2026 |
| Q1 2026 revenue and EPS | Net sales of $844.9 million, diluted EPS of $1.92, and adjusted diluted EPS of $2.13 | West Q1 2026 results | July 9, 2026 |
| Q1 2026 cash and debt | $521.4 million cash and equivalents, $316.2 million total debt, and $205.2 million net cash | StockAnalysis WST balance sheet | July 9, 2026 |
| FY2026 guidance | Net sales guidance of $3.295 billion to $3.350 billion and adjusted diluted EPS guidance of $8.40 to $8.75 | West Q1 2026 results | July 9, 2026 |
| Technical indicators | RSI near 60, 50-day moving average near $332.50, 200-day moving average near $280.70, and mixed MACD signal | AltIndex WST technical analysis | July 9, 2026 |
| Customer concentration | Top ten customers represented 47.6% of 2025 consolidated net sales, with one customer at 15.8% | West 2025 Form 10-K | July 9, 2026 |
This WST AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of July 9, 2026 and can be wrong if fundamentals, guidance, valuation, technical conditions, or market sentiment change.
